Converge Bio Secures $25 Million in Series A Funding Led by Bessemer with Support from Meta, OpenAI, and Wiz Executives
Converge Bio, an AI-driven drug discovery startup, has raised $25 million in a Series A funding round led by Bessemer Venture Partners. Notably, the round also includes investments from prominent executives at Meta, OpenAI, and Wiz, signaling strong confidence in the company’s innovative approach to pharmaceutical research.
